Lymphoma is the fifth most common malignancy in Canada that is expected to cause 2800 deaths and have 7800 new cases this year.
Bendamustine (Treanda) for treatment of Indolent Non-Hodgkin Lymphoma and Mantle Cell Lymphoma
Lymphoma is the fifth most common malignancy in Canada that is expected to cause 2800 deaths and have 7800 new cases this year. The pCODR Expert Review Committee (pERC) recommends funding bendamustine (Treanda) as a first –line therapy in patients with indolent CD20 positive Non-Hodgkin Lymphoma (iNHL) and Mantel Cell Lymphoma (MCL). A recommendation was also submitted for the funding of bendamustine in the relapsed/refractory setting in patients with iNHL and MCL when used in combination with rituximab. The final recommendation was submitted November 29, 2012.
